ArticleBiochemistry2025
Biased Agonists of the Type 1 Angiotensin II Receptor Promote Distinct Subcellular β-Arrestin Conformations.
Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding GPCR signaling in living cells to advance early therapeutic discovery for neurological disorders.Frontiers in molecular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
G protein-coupled receptors (GPCRs) are central to cellular signaling and therapeutic targeting. Ligands that activate the same GPCR can selectively activate some signaling pathways over others, a phenomenon termed biased agonism. Additionally, the same ligand and receptor complex can elicit distinct signaling profiles in different subcellular locations (location bias). Here, we examine how various biased agonists influence the recruitment of β-arrestins 1 and 2 induced by the angiotensin II type 1 receptor at the receptor, plasma membrane, and early endosomes. We also assessed β-arrestin conformational states at the receptor and plasma membrane. Using split luciferase and BRET assays, we demonstrate that angiotensin II, its G protein-biased analogs (TRV055, TRV056), and its β-arrestin-biased analogs (TRV023, TRV026, TRV027, TRV034) functionally stratify into two clusters. G protein-biased agonists and AngII predominantly favor a receptor-β-arrestin core complex conformation driven by engagement of the β-arrestin finger loop with the receptor core. In contrast, β-arrestin-biased agonists promote a tail complex configuration of receptor-associated β-arrestins. However, the conformations of β-arrestins monitored at the plasma membrane were found to be unaffected by ligand bias. Furthermore, balanced and G protein-biased ligands induced higher levels of ERK activation in subcellular locations (nucleus, cytosol, and early endosomes) over the β-arrestin-biased ligands, but equal ERK activity at the plasma membrane. Our findings highlight the interplay between ligand and location biases in dictating GPCR signaling, revealing new insights into the molecular mechanisms driving selective signal propagation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.